AbCellera Biologics WKN: A2QKXS ISIN: CA00288U1066 Kürzel: ABCL Forum: Aktien Thema: Hauptdiskussion

Seine Anteile hat er verkauft

Peter Thiel hat im Februar 2024 angekündigt, seinen Posten im Board von AbCellera zum 7. März 2024 aus persönlichen Gründen niederzulegen. Diese Entscheidung betrifft seine Funktion als Aufsichtsratsmitglied und die damit verbundene Berichtspflicht – sie impliziert jedoch nicht automatisch, dass er seine Beteiligung an AbCellera verkauft hat. Es gibt bislang keine offizielle Mitteilung, die einen Verkauf seiner Anteile bestätigt.

Peter thiel ist komplett raus oder ?

'In a contrasting move, Director John S. Montalbano of AbCellera Biologics made a substantial purchase of 60,000 shares, valued at $140,400. This acquisition stands out amidst the sales and suggests a strong vote of confidence in the company’s future. Montalbano’s decision to invest heavily in AbCellera Biologics could signal anticipated growth or strategic developments on the horizon. This purchase has undoubtedly piqued the interest of investors and market watchers, eager to see how this bold move will play out in the company’s future.' https://www.tipranks.com/news/uncategorized/ambarella-builders-firstsource-sherwin-williams-autozone-abcellera-stock-moves-that-shocked-the-market?mod=mw_quote_news

5x Null

Der macht null Umsatz

Ich sehe für was langfristiges keine Zukunft in dem drecksladen

Und ihr Geld damit gemacht

Die größten haie haben den scheiss geshortet

Abcellera ist eine gute zock aktie

Aber 8 % short ist sehr viel. Ich verkaufe ein Teil wenn es hoch steht und kaufe zu wenn es niedrig steht.

Ich sehe in Abcellera den idealen Hebel gegen die aktuellen Unsicherheiten. Aufgrund der Cash vorrätig hat Abcellera bereits den Wert der Börse. Und sie verkaufen noch nichts, sodass die Auflösung der FDA oder von Medicaid noch keine Auswirkungen hat.

AbCellera Biologics: Strategic Shift and Clinical Advancements Drive Buy Rating Mar 03, 2025, 03:35 PM AbCellera Biologics: Strategic Shift and Clinical Advancements Drive Buy Rating Bloom Burton analyst David Martin PhD has maintained their bullish stance on ABCL stock, giving a Buy rating today. David Martin PhD has given his Buy rating due to a combination of factors that highlight AbCellera Biologics’ potential for growth. Despite the company’s recent financial results showing revenues below expectations, the alignment of earnings per share with forecasts indicates stability in its financial performance. Additionally, the strategic transition from a platform-based model to a pipeline-focused approach is a significant factor in the positive outlook. The imminent entry of two major therapeutic monoclonal antibodies into clinical trials this year underscores the company’s innovative capabilities and potential to capture substantial market opportunities, reinforcing the Buy rating. Martin PhD covers the Healthcare sector, focusing on stocks such as Repare Therapeutics, Aurinia Pharmaceuticals, and ESSA Pharma. According to TipRanks, Martin PhD has an average return of 16.5% and a 46.63% success rate on recommended stocks. https://www.tipranks.com/news/ratings/abcellera-biologics-strategic-shift-and-clinical-advancements-drive-buy-rating?mod=mw_quote_news#google_vignette

Seit 2020 hat abcellera jedes Jahr rekorde gebrochen... Jahr für Jahr ein neues minus Ziel 😅

AbCellera Biologics (ABCL) Gets a Buy from Truist Financial TipRanks Auto-Generated Intelligence Newsdesk Mar 03, 2025, 01:47 PM In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on AbCellera Biologics (ABCL – Research Report), with a price target of $28.00. The company’s shares closed last Friday at $2.59. According to TipRanks, Devarakonda is a 3-star analyst with an average return of 1.5% and a 41.62% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Cytokinetics, and Pfizer. In addition to Truist Financial, AbCellera Biologics also received a Buy from Stifel Nicolaus’s Stephen Willey in a report issued on February 28. However, today, Benchmark Co. maintained a Hold rating on AbCellera Biologics (NASDAQ: ABCL). https://www.tipranks.com/news/blurbs/abcellera-biologics-abcl-gets-a-buy-from-truist-financial-2?mod=mw_quote_news

AbCellera Biologics: Strategic Partnerships and Pipeline Developments Drive Buy Rating TipRanks Auto-Generated Intelligence Newsdesk Mar 03, 2025, 07:58 AM Puneet Souda, an analyst from Leerink Partners, maintained the Buy rating on AbCellera Biologics (ABCL – Research Report). The associated price target is $7.00. Puneet Souda has given his Buy rating due to a combination of factors that highlight AbCellera Biologics as a promising investment. The company is leveraging its substantial liquidity of over $800 million to develop an internal pipeline and establish high-value strategic partnerships. The year 2025 is expected to be significant for AbCellera, with key developments such as the CTA filings for ABCL635 and ABCL575 and the opening of a GMP facility. Additionally, the company plans to disclose the indication for ABCL635, which targets a metabolic condition with a $2 billion total addressable market, and to present preclinical data for ABCL575. Moreover, AbCellera is focusing on difficult targets like GPCR and ion channels, which could differentiate its pipeline and attract strategic partners, especially in light of increasing competition. Although partner programs are no longer the main focus, three partner programs entered Phase I in the fourth quarter, potentially driving future milestone and royalty revenue. The stock is trading near its total liquidity, suggesting potential upside from its royalty portfolio and internal pipeline. These factors contribute to the optimistic outlook and the Buy rating for AbCellera Biologics. In another report released on February 28, Stifel Nicolaus also maintained a Buy rating on the stock with a $10.00 price target. https://www.tipranks.com/news/ratings/abcellera-biologics-strategic-partnerships-and-pipeline-developments-drive-buy-rating?mod=mw_quote_news